Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “The opening of recruitment for patients into our ModiFY clinical trial is a major step forward for the Company. We are very excited about the prospects for Modi-1 based on the dramatic regression of large tumours in our preclinical models and look forward to accelerating recruitment over the coming months and analysing the early safety and immunogenicity data later this year.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.